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Fig.　1　Clinical photographs (a) at the fi rst visit and (b) 21 months after 
starting treatment (remission). (c, d) Histological fi ndings in hematoxylin 
and eosin-stained sections were consistent with scleroderma (original mag-
nifi cation: c, ×1; d, ×100).
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Dear Editor
Correlation between Soluble Interleukin-2
Receptor Levels and Modified Rodnan
Total Skin Thickness Scores in a
Patient with Generalized Morphea:
A Case Report
Generalized morphea is a rare condition in which idi-
opathic sclerosis of the skin occurs in a widespread
manner. It usually starts on the trunk and is not asso-
ciated with systemic disturbances.1 Interleukin-2 re-
ceptor (IL-2R) is a membranous glycoprotein that
forms the high-affinity IL-2 receptor. The soluble
form (sIL-2R) is elevated in most proliferative distur-
bances of the hematopoietic system and in many
solid tumors.2 Here, we describe in detail a correla-
tion between soluble IL-2R levels and modified Rod-
nan total skin thickness scores (mRTSS) in a patient
with generalized morphea treated with topical corti-
costeroids.
A 79-year-old Japanese woman was referred to our
department for diagnosis of sclerotic skin with
erythema on the chest, abdomen, waist, and right
lower leg (Fig. 1a). The sclerotic skin of the abdomen
had a 5-month history and the symptoms gradually
spread to the chest, waist, and right lower leg. She
had no medical history of note. Her younger sister
had died due to collagen disease, but the patient did
not know the accurate diagnosis.
Laboratory tests, including complete blood cell
count, urinalysis, erythrocyte sedimentation rate, and
liver and kidney functions were within normal limits.
However, % eosinophils (12.0%; normal, 0-8%), lactate
dehydrogenase (LDH) (288 IUl ; normal, 114-243
IUl), and serum sIL-2R (1690 Uml; normal, 145-519
Uml) were elevated. Immunoglobulin (Ig) A, IgM,
IgG and complement component 3 (C3) levels were
within normal limits, but C4 (38.6 mgdl; normal, 12-
35 mgdl) and total hemolytic complement (CH50)
(63.0 Uml; normal, 34-49 Uml) levels were slightly
elevated. Autoantibody screening was positive for
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Fig.　2　Clinical course. Administered drugs are shown in the upper part of the fi gure 
and changes in clinical data are shown in the lower section. Soluble interleukin-2 
receptor (sIL-2R, straight line) levels and modifi ed Rodnan total skin thickness 
scores (mRTSS, dotted line) are shown on the left and right axes, respectively.
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rheumatoid factor (18.5 IUml; normal, 0-15 IUml)
and antinuclear antibody (titer, 1 : 80; normal, <1 : 40)
with a speckled and homogenous pattern, and nega-
tive for anticentromere antibody and antitopoisom-
erase I antibodies. The serum level of Krebs von den
Lungen-6 was also within the normal limit.
Chest radiography and computed tomography find-
ings were normal. Pulmonary function tests and data
from electro- and echocardiograms were also within
normal limits. Normal esophageal peristaltic function
was detected by esophagography with barium con-
trast medium. Gastrointestinal endoscopy and colon-
ofiberscopy were also normal, but magnetic reso-
nance imaging of the abdomen showed inflammation
of the fascia.
These results suggested that the diseased area was
limited to the skin (no systemic involvement), leading
to suspicion of generalized morphea or eosinophilic
fasciitis. Therefore, a skin biopsy including the fascia
from the abdomen was performed to discriminate be-
tween these two diseases. The biopsy specimen
showed thickened collagen bundles in the dermis,
the septum of subcutaneous fatty tissue, and the fas-
cia (Fig. 1c). Fatty tissues around the secretory por-
tion of eccrine glands were replaced by thick fibrous
bundles and the eccrine glands were atrophic (Fig.
1d). Eosinophilic infiltration was not found in the fas-
cia. Based on these results, the patient was diagnosed
with generalized morphea. Because of rapid progres-
sion of skin sclerosis, oral therapy with corticoster-
oids was recommended, but she chose topical corti-
costeroid therapy due to her anxiety about possible
systemic side effects.
The mRTSS before treatment was 9. Once-daily
topical application of 0.05% clobetasol propionate oint-
ment was started and within 5 months the mRTSS
had improved to 3 and serum sIL-2R was reduced to
817 Uml (Fig. 2). Topical application of 0.05% clobe-
tasol propionate ointment was continued at a reduced
frequency of once every two days and within 11
months after the start of treatment the mRTSS had
improved to 2 and serum sIL-2R to 732 Uml. At this
time, the treatment was switched to a weaker topical
steroid (0.05% difluprednate applied once every two
days). Within 21 months after the start of treatment,
the mRTSS had a normal value of 0 and the serum
sIL-2R level had similarly normalized at 509 Uml, re-
spectively. The patient has subsequently been in re-
mission for a further 6 months (Fig. 1b).
sIL-2R levels in patients with systemic sclerosis
and localized scleroderma have been reported to be
correlated with disease severity and treatment effi-
cacy.3-6 Uziel et al. described elevated sIL-2R levels in
patients with linear scleroderma in the active phase
(new lesions, increased size of existing lesions, or
erythematous lesions ) compared to the inactive
phase (no new lesions and softening and brownish
discoloration of the skin). However, the current re-
port described in detail correlations among the effi-
cacy of treatment, mRTSS, and serum level of sIL-2R
in a case of generalized morphea. Our case was in the
active phase of generalized morphea based on the
natural clinical course before treatment, and mRTSS
and serum sIL-2R decreased from 9 to 0 and 1690 to
509 Uml, respectively, which clearly correlated with
recovery from the disease.
Recently, cytokine network consisting of IL-17A
and IL-23 is considered related to the pathogenesis of
Generalized Morphea
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scleroderma, 7-9 but the measurement of these cy-
tokine levels may still not be realistic indication. High
resolution B-mode ultrasound is helpful for evaluat-
ing treatment efficacy, but the measurement has poor
reproducibility unless it is performed under the same
conditions by the same operator. Histopathological
examination by skin biopsy is the most reliable
method for evaluation of treatment efficacy, but it is
invasive and our patient refused a skin biopsy during
the treatment course. In contrast, measurements of
the mRTSS and serum level of sIL-2R are safe and
simple, and thus may be especially useful for monitor-
ing disease severity and the response to treatment in
patients with generalized morphea.
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